Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Brazil Reaches Beyond Borders to Strengthen STEM Education

Student

The Brazilian government has set an aggressive goal: To train 101,000 Brazilian students and researchers in top universities worldwide in science, technology, engineering and math (STEM) fields by 2014. Launched in 2011, the Science without Borders program is a Brazilian scholarship program, primarily funded by the government of Brazil, that seeks to strengthen and expand science and technology initiatives, innovation and competitiveness through international mobility of undergraduate and graduate students and researchers. Brazilian students and Read More >

Corporate  |  Leave a comment  |  Email This Post
Tags: , , , ,

2012: A Critical Year for Biotechnology

Capitol

In 2012, we must continue to look for ways to reduce risk; enhance reward; reduce uncertainty; and reinforce the position of the industry as a major contributor resolving society’s most pressing needs. Policies to encourage investment in innovation and to speed discovery to scientific breakthroughs simply must be the priority in 2012. The industry relies on a policy and regulatory environment that encourages innovation for much needed treatments and cures for some of the most Read More >

Public Policy  |  1 Comment  |  Email This Post
Tags: , , , , , ,

Drug Discovery & Development: Partnering for Success…and Survival

There are pressures on Big Pharma and biotech emerging companies alike to engage in more creative deal making to ensure positive outcomes for both parties, Ted Agres writes in Drug Discovery and Development. While the number of deals has remained relatively flat in 2011, the dollar amount of individual deals has increased overall. Oncology remains the most sought after category, followed by CNS, anti-infectives, metabolic diseases, dermatology and cardiovascular. Partnering activity at BIO events is on Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Tap into the Next Generation of Scientists

Biotechnology lab

The importance of mentoring and training students to become scientists has never been more critical as the U.S. aims to maintain its leadership in biotechnology. For students considering a future career path, biotech holds great promise. The industry currently employs 1.42 million Americans in high-wage, high quality jobs while supporting an additional 6.6 million jobs throughout the U.S.  On average, biotech jobs pay roughly two-thirds more than the average annual wage of the total U.S. Read More >

Business and Investments  |  1 Comment  |  Email This Post
Tags: , , ,

BIO Supports SBIR Reauthorization in Senate

Capitol

Last week, the Senate passed the National Defense Authorization Act (S. 1867), which included SBIR reauthorization through Senate Amendment 1115. This is a critical step toward ensuring that all innovative companies can compete for SBIR grants – based on the promise of their science rather than the structure of their capital.  Reauthorizing the program to allow small companies that receive the majority of their financing from venture capital to once again be eligible to compete Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , ,